Sunday July 22, 2018

Integrate National Plans to Eliminate TB by 2030: WHO

The WHO South East Asia Region includes India, Bangladesh, Bhutan, North Korea, Indonesia, Maldives, Myanmar, Nepal, Sri Lanka, Thailand and Timor-Leste

0
//
65
India TB Outreach Work
A TB patient hopeful of being cured in India. Wikimedia
Republish
Reprint

New Delhi, Sep 11, 2017: The World Health Organisation (WHO) has told the South East Asian countries to integrate their national plans and mobilise and utilise resources efficiently to reach the Tuberculosis elimination target of 2030, a statement said on Sunday.

The WHO South East Asia Region includes India, Bangladesh, Bhutan, North Korea, Indonesia, Maldives, Myanmar, Nepal, Sri Lanka, Thailand and Timor-Leste.

Also Read: Malnutrition makes children susceptible to Tuberculosis: Experts 

The global health body said that there is a need for countries to identify the package of interventions best suited to their challenges — whether that means focusing on strengthening TB services, accelerating case detection or investing in research and development.

“All countries face unique challenges, meaning they should each adapt the regional and global strategies to their context,” said a statement issued by the WHO’s South East Asia Region Office.

“We must avoid taking one-size-fits-all approach, and must instead seek out and embrace tailored solutions that meet specific needs and challenges.”

The five-day 70th Regional Committee Session of WHO South East Asia Region concluded in Male on Sunday.

According to the global health body, by planning effectively and making smart, high-impact interventions, countries across the Southeast Asia Region can lift TB’s significant burden and end the disease as a public health threat once and for all.

Although the region accounts for approximately one quarter of the world’s population, it has nearly half the number of new TB cases and close to 40 per cent of TB deaths globally.

In recognition of TB’s outsized burden, accelerating progress towards the 2030 target — which requires a 90 per cent reduction in TB deaths and 80 per cent decrease in TB incidence — is now one of WHO South-East Asia Region’s flagship priority areas of work. (IANS)

Click here for reuse options!
Copyright 2017 NewsGram

Next Story

Cepheid to Establish Manufacturing Unit for TB Diagnostics in India

Rifampicin is a drug commonly used in treating TB bacteria in first line of treatment

0
The GeneXpert Edge is developed specifically for near-patient testing, to help support a one visit test-and-treat approach.
The GeneXpert Edge is developed specifically for near-patient testing, to help support a one visit test-and-treat approach. (IANS)

Expanding its footprint in India, US-based molecular diagnostics company Cepheid Inc on Thursday announced its plans to establish a manufacturing unit in the country to improve Tuberculosis (TB) diagnostics.

Cepheid’s GeneXpert MTB/RIF test is a closed-cartridge-based system that is easy to operate by minimally trained staff and gives results in approximately two hours, speeding the conventional backlog that used to exist in traditional diagnostic methods.

The new manufacturing unit would produce MTB/RIF test cartridges, contribute to the government’s “Make in India” initiative and thus bringing the company’s global expertise in TB diagnostics to India, the company said in a statement.

As part of the plan, Cepheid also unveiled its latest portable, easy-to-use TB-testing system — the GeneXpert Edge — which is expected to be available in India later this year, the company said.

The GeneXpert Edge is developed specifically for near-patient testing, to help support a one visit test-and-treat approach.

“Cepheid recognises the need for technological advancement and is committed to contributing significantly to India’s goal of TB eradication,” said Peter Farrell, Executive Vice President, Worldwide Commercial Operations, Cepheid.

Cepheid's Xpert MTB/RIF test has the potential to detect Mycobacterium tuberculosis(MTB)
Cepheid’s Xpert MTB/RIF test has the potential to detect Mycobacterium tuberculosis(MTB).

“We are hopeful that GeneXpert Edge will help eliminate delays in TB diagnostics by providing definitive results within hours and facilitating fast and easy last-mile delivery even in the remote villages of India,” he added.

India has nearly one-fourth of the global TB patients and an estimated 4.8 lakh lives are lost every year due to delayed diagnosis and inadequate treatment and there are above 2.5 million new cases of TB every year. The country aims to eradicate TB by 2025.

Approved by the World Health Organisation (WHO) in 2010, more than 1,200 Cepheid’s GeneXpert Systems have been installed in the last two years at various Revised National Tuberculosis Control Programme (RNTCP) sites in the country and more than 2.5 million cartridges were supplied last year at various centres of Central TB Division (CTD).

Also Read: Fruit Bats Identified As Source Of Nipah Virus Outbreak in Kerala

Cepheid’s Xpert MTB/RIF test has the potential to detect Mycobacterium tuberculosis(MTB) and rifampicin-resistance mutations, which are markers for MDR-TB strains in under two hours.

Rifampicin is a drug commonly used in treating TB bacteria in first line of treatment.

Xpert MTB/RIF tests also have excellent negative predictive value, which allows clinicians to manage TB-negative patients more effectively to prevent unnecessary and costly respiratory isolations. (IANS)